Mestastop Solutions have signed a memorandum of understanding with Syngene to provide its proprietary platform for metastasis discovery on a non-exclusive basis to Syngene clients, as per certain terms and conditions. Mestastop, a start-up biotech that specializes in the understanding of cancer metastasis drug discovery and diagnostics, is currently working on metastasis translational models, with patient primary tumors. Syngene is an integrated research, development, and manufacturing organization providing scientific services from early discovery to commercial supply.

Under this agreement, all pre-existing intellectual property will remain the property of the respective party and either party shall have no right or license to the other intellectual property. Mestastop will be the sole and exclusive owner of all intellectual property claiming or covering assays. Syngene and their clients shall be the exclusive owner of the work product generated by Mestastop as a result of the performance of the services.

Speaking on this MOU, Dr. Arnab Roy Chowdhury, Founder/Director of Mestastop Solutions said; “During my time with Amgen, I have worked with Syngene and have realized why they are so special. The quality of their scientists and special attention to data integrity and safety are some of the reasons they are one of the world leaders and it is indeed an honor for Mestastop to have our assays recognized and validated by Syngene’s excellent scientific team and leadership.  We are new entrants in this biotech ecosystem and have big dreams of pursuing innovation in India, and this partnership will fuel us with that revenue which we require for our future growth”.

Dr. Atul Tiwari, Deputy Director of Syngene and Head of assay biology & screening said; “Syngene is happy to partner with Mestastop to utilize their metastasis assay platform in providing meaningful insights to our oncology discovery programs. Syngene will provide end-to-end capabilities in oncology drug discovery as services to Mestastop as well”

More about Mestastop: Cancer metastasis, a complex biological process, is responsible for 90% of cancer-related deaths. Mestastop has successfully translated the metastasis biology into in vitro phenotypic assays each representing a particular step in metastasis. With their partners, Immunobiome, they have successfully established novel spontaneous metastasis animal models that work in only six weeks. The colorectal cancer-based platform was presented at the 2021 AACR meeting and was widely accepted, appreciated by Industry and academic peers.  Currently working on a triple-negative breast cancer platform, Mestastop is also analyzing patient primary tumor samples to understand their metastasis characteristics and probability. For more details, visit www.mestastop.com.

More about Syngene: Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 4700 scientists offer both skills and the capacity to deliver great science, robust data management, and IP security and quality manufacturing at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb, and Herbalife, as well as 2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. For more details, visit www.syngeneintl.com.